Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden

Table 6 Base case inputs and assumptions

Variable	Description	References
Time horizon	Life time	Assumption
Start age	65 years	Based on [17] (mean)
Sex	Both	Assumption
Treatment duration	4 years	Based on [17] length
Cost of tiotropium	SEK 12.77 per day	[36]
Cost of glycopyrronium	SEK 10.48 per day	[36]
Discount rate	3 % per annum (both effects and costs)	[37]
Initial prob	GOLD II: 48 %, GOLD III: 44 %, GOLD IV: 8 %	[17]
Transition prob	Probabilities (3-month)	[28]
Mortality states	GOLD, age and sex dependent	[10, 32, 33]
Mortality severe ex	Excess mort increasing with age	[33]
Exacerbation risks	Probabilities (3-month)	[20, 28]

ISSN: 1478-7547